FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient's continued service with the Company through the ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...

A new study revealed that these programs may ... Study Finds New Link Between Food Choices, Depression and Alzheimer's Disease Feb. 5, 2025 — New research has shown that diet could influence the ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Depression has been recently linked to the visual cortex. Here, the authors identify a glutamatergic primary visual corticallateral posterior thalamic nucleus circuit and its key regulator, Gγ4 ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.